Advertisement

History of Hematopoietic Cell Transplantation

  • Jaroslava SalmanEmail author
  • Kimberly Shapiro
  • Stephen J. Forman
Chapter

Abstract

Every year, thousands of people around the country are diagnosed with a blood cancer. Hematopoietic stem cell transplant (HSCT) is a potentially lifesaving treatment for more than 70 different diseases, including leukemia, lymphoma, myelodysplastic syndrome, inherited immune deficiency disorders, and others. The history of HSCT began in the wake of the first atomic bomb explosions and led to landmark observations about mice being protected from the lethal effects of ionizing radiation on the bone marrow by shielding their spleens with lead. Subsequent experiments allowed for further development of this revolutionary treatment modality and ultimate success in efforts to treat patients with hematological diseases which have previously been inevitably lethal. The history of HSCT is a timeline of many groundbreaking discoveries, and numerous scientific lessons learned in the early days of HSCT are still relevant today. Although much has been learned over the last decades, use of old and new insights in HSCT will continue to be combined to identify the most effective treatment options.

Keywords

Autologous/allogeneic hematopoietic stem cell transplant Graft-versus-host disease Irradiation Chemotherapy Human leukocyte antigen Donor Stem cells History 

Notes

Glossary of Terms

Autologous

Cells derived from the same individual.

Allogeneic

Cells obtained from a genetically distinct individual of the same species.

Cellular Factor

Aspect of the immune response related to white blood cells, rather than circulating antibodies.

CMV (Cytomegalovirus)

A herpes virus that becomes latent after primary infection and causes few symptoms in the general population. However, it can reactivate in immunosuppressed transplant patients and is a significant cause of morbidity and mortality due to infection of multiple organs including the lungs, gastrointestinal tract, and central nervous system.

CSF (Colony-Stimulating Factors)

Proteins that bind to receptors on the surface of hematopoietic stem cells, activating them to proliferate and differentiate into a specific kind of blood cell.

Conditioning Regimen

Treatments used to prepare a patient for stem cell transplant. May involve chemotherapy, monoclonal antibody therapy, and radiation treatments of the entire body.

Cryopreservation

A process of cooling cells to very low temperatures to preserve structure and function.

Cytogenetics

Branch of genetics concerned with the structure and function of chromosomes.

HCT (Hematopoietic Cell Transplantation)

Also referred to as a bone marrow transplant, HCT is a procedure that infuses healthy blood stem cells into the body to replace diseased or damaged bone marrow.

Hematopoietic

The formation of blood.

HLA (Human Leukocyte Antigen)

A protein marker found on most cells in the body used to determine a match for bone marrow.

Humoral Factor

Immune responses involving antibodies in body fluids.

Murine

Affecting mice or related rodents.

Myeloablative Chemotherapy

High-dose chemotherapy that kills cells in the bone marrow, including cancer cells and normal blood-forming cells in the marrow. It is usually followed by a bone marrow transplant.

PCR (Polymerase Chain Reaction)

A technique used in molecular biology to amplify a single copy or a few copies of a piece of DNA. This can generate up to millions of copies of a particular DNA sequence for further study.

References

  1. 1.
    Cooper B. The origins of bone marrow as the seedbed of our blood: from antiquity to the time of Osler. PRO. 2011;24(2):115–8.Google Scholar
  2. 2.
    Blume KG, Thomas ED. A history of allogeneic and autologous hematopoietic cell transplantation. In: Thomas’ hematopoietic cell transplantation. 5th ed. San Francisco: Wiley Blackwell; 2016. p. 1–11.Google Scholar
  3. 3.
    Snell GD. Methods for the study of histocompatibility genes. J Genet. 1948;49(2):87–108.CrossRefGoogle Scholar
  4. 4.
    Medawar PB. The immunology of transplantation. Harvey Lect. 1956;(Series 52):144–76.Google Scholar
  5. 5.
    Little MT, Storb R. History of haematopoietic stem-cell transplantation. Nat Rev Cancer. [Review]. 2002;2(3):231–8.CrossRefGoogle Scholar
  6. 6.
    Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257(11):491–6.CrossRefGoogle Scholar
  7. 7.
    Ezzone SA. History of hematopoietic stem cell transplantation. Semin Oncol Nurs. [Article]. 2009;25(2):95–9.CrossRefGoogle Scholar
  8. 8.
    Dausset J. Iso-leuko-antibodies. Acta Haematol. 1958;20(1–4):156–66.CrossRefGoogle Scholar
  9. 9.
    Van Rood JJ, Eernisse JG, Van Leeuwen A. Leucocyte antibodies in sera from pregnant women. Nature. 1958;181(4625):1735–6.CrossRefGoogle Scholar
  10. 10.
    Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, et al. Bone-marrow transplantation (first of two parts). N Engl J Med. 1975;292(16):832–43.CrossRefGoogle Scholar
  11. 11.
    Smith KO, Galloway KS, Kennell WL, Ogilvie KK, Radatus BK. A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1982;22(1):55–61.CrossRefGoogle Scholar
  12. 12.
    Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harb Symp Quant Biol. 1986;51(Pt 1):263–73.CrossRefGoogle Scholar
  13. 13.
    Bortin MM, Horowitz MM, Gale RP. Current status of bone marrow transplantation in humans: report from the international bone marrow transplant registry. Nat Immun Cell Growth Regul. 1988;7(5–6):334–50.PubMedGoogle Scholar
  14. 14.
    Ballen KK. New trends in umbilical cord blood transplantation. Blood. 2005;105(10):3786–92.CrossRefGoogle Scholar
  15. 15.
    Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17):1874–83.CrossRefGoogle Scholar
  16. 16.
    Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transpl. 2005;11(12):945–56.CrossRefGoogle Scholar
  17. 17.
    Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(12):1530–8.CrossRefGoogle Scholar

Additional References

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Jaroslava Salman
    • 1
    Email author
  • Kimberly Shapiro
    • 1
  • Stephen J. Forman
    • 2
  1. 1.Department of Psychiatry and PsychologyCity of HopeDuarteUSA
  2. 2.Department of Hematology and Hematopoietic Cell TransplantationCity of HopeDuarteUSA

Personalised recommendations